GLP-1 Medications and Sleep Apnea: What the Research Reveals

If you have been diagnosed with obstructive sleep apnea, you know the routine. The machine on your nightstand. The mask. The nightly ritual that helps you breathe, but does not fix the underlying problem.

What you may not know is that a class of medications originally developed for blood sugar control, and now widely used for weight management, has become the first drug ever approved specifically to reduce sleep apnea severity in people with obesity.

This is not a side effect. It is not a secondary finding. In December 2024, the FDA granted an official indication to tirzepatide for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, based on data from the largest placebo-controlled sleep apnea drug trial ever run.

Here is what the research shows, how GLP-1 medications appear to affect sleep-disordered breathing, and what this might mean for you.

*Compounded tirzepatide is not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical trial data cited here was gathered using FDA-approved formulations. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

What Is Obstructive Sleep Apnea?

Obstructive sleep apnea happens when the muscles in your throat relax too much during sleep. Your airway narrows or closes completely, you stop breathing for a moment, your oxygen level drops, and your brain sends a signal to wake you up enough to restore airflow. This cycle can repeat dozens or even hundreds of times per night.

Most people with OSA do not remember waking up. What they feel instead is unrefreshing sleep, morning headaches, difficulty concentrating, irritability, and a level of daytime fatigue that does not respond to more hours in bed.

The scale of the problem is substantial. A systematic review published in *Sleep Medicine Reviews* (PMID: 27568340) found that OSA affects between 9% and 38% of the general population depending on diagnostic criteria. In older adults and in people with higher body weight, rates climb significantly higher. Obesity is one of the strongest known risk factors for OSA, which is why effective weight management is a central pillar of OSA treatment guidelines.

Standard treatment is continuous positive airway pressure therapy, better known as CPAP. CPAP works by delivering a steady stream of pressurized air through a mask to keep your airway open while you sleep. It is effective for most people who use it consistently. The challenge is consistency. Adherence rates vary widely, and many people find the mask uncomfortable, especially in the early months of treatment.

This is the gap that GLP-1 research is beginning to address.

---

The Obesity-Sleep Apnea Connection

To understand why GLP-1 medications are being studied for sleep apnea, you need to understand what obesity does to the airway.

Excess fat deposits around the neck and throat narrow the upper airway, making collapse during sleep more likely. Fat accumulation in the chest and abdomen also reduces lung volume and changes how the diaphragm functions, which affects breathing mechanics throughout the night. When you lose weight, these structural pressures ease. For many people with OSA, even a 10% reduction in body weight meaningfully reduces the number of breathing interruptions per hour.

The STEP 1 trial, published in the *New England Journal of Medicine* in 2021 (PMID: 33567185), showed that adults with obesity who took semaglutide 2.4 mg once weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo and lifestyle changes alone. Those kinds of reductions, if sustained, have real implications for airway anatomy.

But the conversation around GLP-1 medications and sleep apnea does not stop at weight loss. Researchers are also looking at whether GLP-1 receptor activity in the brain and peripheral tissues might have more direct effects on breathing regulation during sleep. The evidence here is preliminary, but it is generating serious scientific interest.

---

The SURMOUNT-OSA Trial: What the Data Shows

The most important piece of evidence in this space comes from the SURMOUNT-OSA trial, published in the *New England Journal of Medicine* in 2024 (PMID: 38912654).

Led by Dr. Atul Malhotra and colleagues, the trial enrolled adults with moderate-to-severe obstructive sleep apnea and obesity in two parallel studies. Trial 1 included participants who were not currently using CPAP. Trial 2 included participants who were already on CPAP therapy. Participants were randomly assigned to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or a placebo, once weekly, for 52 weeks.

The primary outcome measure was the apnea-hypopnea index (AHI), which counts the number of breathing interruptions per hour of sleep. A normal AHI is below 5. Moderate OSA is 15 to 30. Severe OSA is above 30.

The results were substantial.

In Trial 1, tirzepatide reduced AHI by an average of 25.3 events per hour, compared to 5.3 events per hour with placebo. In Trial 2, tirzepatide reduced AHI by 29.3 events per hour versus 5.5 with placebo. These reductions translated to a roughly 63% mean decrease in breathing interruptions per hour.

Beyond AHI, the trial also tracked oxygen deprivation burden (how much time participants spent with low blood oxygen at night), systemic inflammation markers (hsCRP), systolic blood pressure, and patient-reported sleep quality. Tirzepatide showed significant improvements across all of these measures.

Approximately half of participants in the tirzepatide groups met criteria for disease resolution, defined as an AHI below 5 events per hour at the end of the trial. That is a meaningful number. For a condition historically managed rather than resolved, reaching clinical resolution in a substantial proportion of participants is a significant finding.

*Clinical trial data referenced above was gathered using FDA-approved tirzepatide formulations. Compounded tirzepatide is not FDA-approved and has not been studied in dedicated sleep apnea trials.*

---

What Broader GLP-1 Research Suggests

The SURMOUNT-OSA trial focused on tirzepatide. A 2024 scoping review published in *Pharmacy (Basel)* (PMID: 38251405) looked more broadly at the available evidence across GLP-1 receptor agonists and sleep apnea. It identified nine studies examining this relationship and found early signals of benefit consistent across the class.

The authors noted that GLP-1 medications appear to reduce AHI through a combination of weight loss and possible direct effects on the upper airway or breathing regulation. However, they also acknowledged that evidence quality was mixed, with many of the studies being observational rather than randomized controlled trials. Their overall conclusion: more rigorous research is needed before GLP-1 medications are formally integrated into OSA treatment guidelines outside of the tirzepatide indication.

This is an honest assessment. What the broader evidence suggests is a biological relationship worth investigating. What the SURMOUNT-OSA trial established is one specific data point of high quality. The full picture is still being assembled.

---

Safety and Side Effects

In the SURMOUNT-OSA trial, the most common side effects with tirzepatide were gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are the same effects seen across GLP-1 trials and are typically most pronounced during dose escalation. Most participants experienced them as mild to moderate and temporary. Treatment discontinuation due to side effects occurred in a small minority of participants.

Tirzepatide and other GLP-1 medications are not appropriate for everyone. People with a personal or family history of medullary thyroid carcinoma, or those with multiple endocrine neoplasia syndrome type 2 (MEN2), should not use these medications. Pancreatitis has been reported in some GLP-1 users, though causality remains under investigation. Your healthcare provider will review your full medical history before prescribing.

Because OSA is a serious medical condition with established cardiovascular and metabolic consequences, any approach to managing it, including medication, should be discussed with your doctor and, where relevant, coordinated with a sleep specialist.

---

What This Means for Your Sleep Apnea

Sleep apnea and obesity often show up together, and they reinforce each other. Disrupted sleep makes weight management harder. Excess weight makes breathing worse during sleep. Breaking that cycle has always been the challenge.

GLP-1 medications, particularly tirzepatide, represent a new tool in that effort. For people who struggle with CPAP adherence, or for those who want to address the root metabolic drivers of their condition, the data from SURMOUNT-OSA offers a concrete and well-powered reason to have a conversation with their provider about GLP-1 options.

This does not mean GLP-1 medications replace CPAP. For people with severe OSA, CPAP remains the most reliable intervention. What GLP-1 research suggests is that combination approaches, treating both the structural anatomy of OSA (with CPAP) and its primary risk factor (weight, with GLP-1 therapy), may produce better outcomes than either approach alone.

---

Compounded Tirzepatide: A Prescriva Overview

Prescriva connects patients with licensed providers who can evaluate whether compounded tirzepatide may be appropriate for their situation. If a provider determines that a compounded formulation is clinically appropriate, medications are prepared by state-licensed 503A compounding pharmacies that operate under state pharmacy board oversight and follow USP compounding standards.

Compounded tirzepatide is not FDA-approved and is not the same as Zepbound or any other branded product. It is prescribed based on individual patient need after a full medical evaluation. The FDA indication for tirzepatide in sleep apnea applies to the FDA-approved branded formulation, not to compounded versions.

---

The Bottom Line

Obstructive sleep apnea is more common than most people realize, and obesity is one of its strongest risk factors. The SURMOUNT-OSA trial, published in the *New England Journal of Medicine* in 2024, established that tirzepatide significantly reduced sleep apnea severity in adults with obesity, with approximately half of participants reaching AHI levels consistent with disease resolution.

This is meaningful progress in a condition that has historically been managed rather than resolved for most patients.

If you have sleep apnea and are also working on weight management, this connection is worth discussing with your healthcare provider. Weight loss through a medically supervised program can reduce the structural drivers of airway obstruction, and the data now supports a direct pharmacological effect as well.

Ready to explore your options? [Check your eligibility for a Prescriva consultation](/resources/who-qualifies-for-glp1-medications) and speak with a licensed provider about whether a GLP-1 program may be appropriate for your health goals.

*This article is for informational and educational purposes only. It does not constitute medical advice. Compounded medications are not FDA-approved. Clinical trial data cited here reflects research conducted with FDA-approved formulations. Individual results vary. Consult your licensed healthcare provider before making any changes to your treatment plan.*

---

Sources

1. Malhotra A et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity." *New England Journal of Medicine*. 2024. PMID: 38912654.

1. Senaratna CV et al. "Prevalence of obstructive sleep apnea in the general population: A systematic review." *Sleep Medicine Reviews*. 2017. PMID: 27568340.

1. Le KDR et al. "The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review." *Pharmacy (Basel)*. 2024. PMID: 38251405.

1. Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." *New England Journal of Medicine*. 2021. PMID: 33567185.